Table 1.

Descriptive statistics of study population with a measurement of IgG.

	Pancreatic cancer N = 689 n (%)	No pancreatic cancer N = 135,532 n (%)
Mean Age (years) (SD)	55.8 (11.37)	47.1 (14.33)
<55	319 (46.30)	95,342 (70.35)
≥55	370 (53.70)	40,190 (29.65)
Gender
Men	388 (56.31)	68,995 (50.91)
Women	301 (43.69)	66,537 (49.09)
SES
Unclassified/missing	74 (10.74)	13,561 (10.01)
Low	283 (41.07)	59,611 (43,98)
High	332 (48.19)	62,360 (46.01)
Education
Missing	109 (15.82)	8,594 (6.34)
Low	211 (30.62)	37,876 (27.95)
Middle	241 (34.98)	55,617 (41.04)
High	128 (18.58)	33,445 (24.68)
Charlson Comorbidity Index
0	622 (90.28)	126,594 (93.41)
1	49 (7.11)	6,265 (4.62)
2	13 (1.89)	1,565 (1.15)
3+	5 (0.73)	1,108 (0.82)
Mean follow-up time (years) (SD)	13.1 (7.64)	21.3 (6.67)
Glucose (mmol/L)
Mean (SD)	5.34 (1.71)	5.01 (1.28)
<5.60 mmol/L	501 (72.71)	107,538 (79.35)
5.60–6.99 mmol/L	107 (15.53)	14,352 (10.59)
≥7.00 mmol/L	48 (6.97)	4,040 (2.98)
Missing	33 (4.79)	9,602 (7.08)
IgG (g/L)
Mean (SD)	11.17 (2.77)	11.55 (3.03)
<6.10 g/L	14 (2.03)	1,493 (1.10)
6.10–14.99 g/L	601 (87.23)	116,704 (86.11)
≥15.00 g/L	74 (10.74)	17,335 (12.79)